Seminars in Hematology
Volume 46, Supplement 2 , Pages S44-S58, January 2009

Therapeutic Approaches to Secondary Immune Thrombocytopenic Purpura

  • James B. Bussel

      Affiliations

    • Corresponding Author InformationAddress correspondence to James B. Bussel, MD, Platelet Disorders Center, Division of Pediatric Hematology-Oncology, Weill Cornell Medical College of Cornell University, 525 E 68th St, P-695, New York, NY 10021

Platelet Disorders Center, Division of Pediatric Hematology-Oncology, Weill Cornell Medical College of Cornell University, New York, NY

Secondary thrombocytopenia is similar to primary or idiopathic thrombocytopenia (ITP) in that it is characterized by reduced platelet production or increased platelet destruction resulting in platelet levels <60,000/μL. Thrombocytopenia can occur from secondary causes associated with chronic disorders or with disturbed immune function due to chronic infections, lymphoproliferative and myeloproliferative disorders, pregnancy, or autoimmune disorders. Diagnosis of secondary ITP in some cases is complex, and the thrombocytopenia can often be resolved by treating the underlying disorder to the extent this is possible. In most cases, treatment is focused on reducing platelet destruction, but, in some cases, treatment may also be directed at stimulating platelet production. The most problematic cases of thrombocytopenia may be seen in pregnant women. This review will address various agents and their utility in treating ITP from secondary causes; in addition, thrombocytopenia in pregnancy, ITP in immunodeficiency conditions, and drug-induced thrombocytopenia will be discussed. Unlike primary ITP, treatment often must be tailored to the specific circumstance underlying the secondary ITP, even if the condition itself is incurable.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 STATEMENT OF CONFLICT OF INTEREST: James B. Bussel, MD, discloses the following: Consultant/Advisory Board: Amgen, GSK, Ligand, Baxter; Speaker Programs: Baxter; Investigator: Amgen, GSK, Ligand, Biogenldec, Cangene, Genentech, Genzyme, Immunomedics, MGI Pharma, Sysmex; Stockholder (Spouse): Amgen, GSK.

PII: S0037-1963(08)00202-3

doi:10.1053/j.seminhematol.2008.12.003

Seminars in Hematology
Volume 46, Supplement 2 , Pages S44-S58, January 2009